No child left behind: Enrolling children and adults simultaneously in critical care randomized trials

Critical Care Medicine

Volumn 37, Issue 9, 2009, Pages 2638-2641

  Halpern, Scott D ^a   Randolph, Adrienne G ^b   Angus, Derek C ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Bayesian; Critical care; Institutional Review Board; Pediatrics; Randomized trials; Research ethics; Subgroup analyses

Indexed keywords

ARTICLE; BAYES THEOREM; CRITICAL ILLNESS; INSTITUTIONAL REVIEW; INTENSIVE CARE; MEDICAL RESEARCH; METHODOLOGY; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; RESEARCH ETHICS; RESEARCH SUBJECT; RISK ASSESSMENT; WELLBEING;

EID: 69349104085     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181a59357     Document Type: Article

References (38)

1. Gill D: Ethical principles and operational guidelines for good clinical practice in paediatric research. Recommendations of the Ethics Working Group of the Confederation of European Specialists in Paediatrics (CESP). Eur J Pediatr 2004; 163:53-57
2. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report. Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC, US Government Printing Office, 1979
3. Nadel S, Goldstein B, Williams MD, et al: Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial. Lancet 2007; 369: 836-843 (Pubitemid 46365900)
4. Nichols DG: Conversation within the specialty: how, whom, and what shall we study? Pediatr Crit Care Med 2006; 7:386-387
5. Regulation (EC) No 1901/2006 of the European Parliament. Available at http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/reg-2006-1901/ reg-2006-1901-en.pdf. Accessed March 8, 2008
6. Pediatric Research Equity Act of 2007 (Title IV of the Food and Drug Administration Amendments Act of 2007). Available at http://www.fda.gov/oc/ initiatives/HR3580.pdf. Accessed March 5, 2008
7. Institute of Medicine (IOM): The Ethical Conduct of Clinical Research Involving Children. Washington, DC, National Academy of Sciences, 2004
8. NIH Policy and Guidelines on the Inclusion of Children as Participants in Research Involving Human Subjects. 1998. Available at http://grants.nih.gov/ grants/guide/notice-files/not98-024.html. Accessed June 17, 2008
9. Caldwell PHY, Murphy SB, Butow PN, et al: Clinical trials in children. Lancet 2004; 364: 803-811
10. Hebert PC, Wells G, Blajchman MA, et al: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340:409-417 (Pubitemid 29084771)
11. Lacroix J, Hebert PC, Hutchison JS, et al: Transfusion strategies for patients in pediatric intensive care units. N Engl J Med 2007; 356:1609-1619 (Pubitemid 46631670)
12. t Jong GW, Vulto AG, de Hoog M, et al: A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics 2001; 108:1089-1093
13. Steinbrook R: Testing medications in children. N Engl J Med 2002; 347:1462-1470
14. Jonas H: Philosophical reflections on experimenting with human subjects. In: Experimentation with human subjects. Freund PA (Ed). New York, George Braziller,1970, pp 1-31
15. Kipnis K: Seven vulnerabilities in the pediatric research subject. Theor Med Bioeth 2003; 24:107-120
16. Karlawish JHT: Research involving cognitively impaired adults. N Engl J Med 2003; 348:1389-1392
17. Luce JM, Cook DJ, Martin TR, et al: The ethical conduct of clinical research involving critically ill patients in the United States and Canada: Principles and recommendations. Am J Respir Crit Care Med 2004; 170: 1375-1384
18. Truog RD: Will ethical requirements bring critical care research to a halt? Intensive Care Med 2005; 31:338-344
19. Nelson RM, Ross LF: In defense of a single standard of research risk for all children. J Pediatr 2005; 147:565-566
20. Wendler D, Belsky L, Thompson KM, et al: Quantifying the federal minimal risk standard: Implications for pediatric research without a prospect of direct benefit. JAMA 2005; 294:826-832 (Pubitemid 41178967)
21. Fan E, Shahid S, Kondreddi VP, et al: Informed consent in the critically ill: A twostep approach incorporating delirium screening. Crit Care Med 2008; 36:94-99
22. Weijer C. The ethical analysis of risk. J Law Med Ethics 2000; 28:344-361
23. National Bioethics Advisory Commission: Assessing risks and potential benefits and evaluating vulnerability. In: Ethical and Policy Issues in Research Involving Human Participants. Vol 1. Bethesda, MD, National Bioethics Advisory Commission, 2001, pp 69-96
24. Bernard GR, Vincent J-L, Laterre P-F, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709 (Pubitemid 32204987)
25. The Acute Respiratory Distress Syndrome Network: Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000; 342:1301-1308
26. The National Heart Lung and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Comparison of two fluidmanagement strategies in acute lung injury. N Engl J Med 2006; 354:2564-2575
27. Pronovost P, Needham D, Berenholtz S, et al: An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006; 355:2725-2732 (Pubitemid 46021509)
28. Elward AM, Fraser VJ: Risk factors for nosocomial primary bloodstream infection in pediatric intensive care unit patients: A 2-year prospective cohort study. Infect Control Hosp Epidemiol 2006; 27:553-560
29. Kollef MH, Shapiro SD, Silver P, et al: A randomized, controlled trial of protocoldirected versus physician-directed weaning from mechanical ventilation. Crit Care Med 1997; 25:567-574 (Pubitemid 27193967)
30. Randolph AG, Wypij D, Venkataraman ST, et al: Effect of mechanical ventilator weaning protocols on respiratory outcomes in infants and children: A randomized controlled trial. JAMA 2002; 288:2561-2568 (Pubitemid 35386891)
31. Halpern SD, Karlawish JHT, Berlin JA: The continuing unethical conduct of underpowered clinical trials. JAMA 2002; 288:358-362 (Pubitemid 34761615)
32. Goldstein B, Giroir B, Randolph A: International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6:2-8 (Pubitemid 40956461)
33. Kent DM, Hayward RA: Limitations of applying summary results of clinical trials to individual patients: The need for risk stratification. JAMA 2007; 298:1209-1212
34. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310 (Pubitemid 32641789)
35. Assmann SF, Pocock SJ, Enos LE, et al: Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000; 355: 1064-1069 (Pubitemid 30162810)
36. White IR, Pocock SJ, Wang D: Eliciting and using expert opinions about influence of patient characteristics on treatment effects: A Bayesian analysis of the CHARM trials. Stat Med 2005; 24:3805-3821
37. Berry DA: Bayesian statistics and the efficiency and ethics of clinical trials. Stat Sci 2004; 19:175-187 (Pubitemid 39056885)
38. United States Congress: Food and Drug Administration Amendments Act of 2007. Available at: http://frwebgate.access.gpo.gov/cgibin/getdoc.cgi?dbname= 110-cong-public-laws&docid=f:publ085.110.pdf. Accessed July 7, 2009